Mirdametinib and Carbamazepine

Phase 2Small molecule

Mirdametinib and Carbamazepine is one of 24 small molecule programs targeting Plexiform Neurofibroma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plexiform NeurofibromaActive, not recruiting

CARNot yet recruiting

Plexiform NeurofibromaPhase 2

Active, not recruiting

CARPhase 1

Not yet recruiting

Competition

Competitive Landscape

36 competitors in CAR

#DrugCompanyPhaseTrials

Isopto Carpine

AAdvanz Pharma

Phase 3

3 2

Floxin

WWim Janssens

Phase 3

1 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Pelacarsen

Novartis

Phase 3

1 5

L-Carnitine

IIperboreal Pharma Srl

Phase 3

1 6

Tegretol

Novartis

Phase 1

10 7

Verquvo

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2

1 8

Tylenol

KKenvue Brands

Phase 2

1 9

Diamox

Teva

Phase 1

2 10

Trileptal

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

CAR

NCT07279233

Q4 2028

Phase 2Active, not recruiting

Plexiform Neurofibroma

NCT03962543

Clinical

Trials by Indication[1]

CAR1 trial

To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants

Not yet recruiting·SSpringWorks Therapeutics, Inc.·Phase 1·NCT07279233·36 enrolled

Plexiform Neurofibroma1 trial

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity

Active, not recruiting·SSpringWorks Therapeutics, Inc.·Phase 2·NCT03962543·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Mirdametinib and Carbamazepine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mirdametinib and Carbamazepine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mirdametinib and Carbamazepine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SpringWorks Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSpringWorks Therapeutics, Inc.

Mirdametinib and Carbamazepine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Trials by Indication[1]

CAR1 trial

Plexiform Neurofibroma1 trial

References

Drug Info

Quick Facts

Related News